GD2 gangliosides are widely expressed on the surface of neuroblastoma cells. Neuroblastoma (NB) is one of the most common pediatric neuroendocrine tumors. The present invention pertains to a bacteriophage, or a composition containing it, that includes and/or expresses at least one ligand targeting disialoganglioside (GD2), and its medical or diagnostic uses.  

Through the utilization of an engineered filamentous M13 phage vector, there exists the capability to selectively deliver substantial amounts of therapeutic molecules (such as photosensitizers, sonosensitizers, chemotherapeutics, etc.) to GD2+ tumor cells, thereby inducing their cellular demise. This system furnishes compelling evidence of specificity and sensitivity for GD2+ cells while demonstrating a lack of binding to GD2-negative cells.

• Biotechnology sector;
• Biomedical sector;
• Pharmaceutical sector;
• Therapeutic;
• Diagnostic fields.

• Detection and targeted ablation of GD2+ cells;
• Non-invasive and targeted anticancer therapies.